Rosetta Genomics Ltd (ROSGQ)

[dude iligence]

dmlabuda how long have you been trading? Do you know anything about how dilution works. I posted to you a few post ago (by the way which have been removed) that a 3 second look at the chart told me ROSG nothing more than a Diluted POS pennystock. It has a very distinctive chart pattern you won't find in any book or table. I refer to it as the dilution shzz slide chart.

http://stockcharts.com/h-sc/ui?s=ROSG&p=D&b=5&g=0&id=p06186303256

Since then I looked at the pr's

Delisting coming Kiss of Death followed by dilutive financing

Rosetta Genomics Company Profile: Rosetta Genomics develops and commercializes new diagnostic tests based on microRNAs, which the company says play an important role in normal function and in various pathologies. Current Share Price: 55 cents (Feb. 28) Listing Violation: Bid price. The listing rule requires that a company maintains a minimum closing bid price of $1 per share for its common stock. Rosetta Genomics shares last closed above $1 on Dec. 22. The company was hit in December with a separate delisting warning related to market value, equity and net income. Received Nasdaq Notice: Feb. 7 Management's Expected Action: Rosetta Genomics has until Aug. 8 to regain compliance with the minimum bid price requirement. While the company did not offer any indication of what it may do to regain compliance with the rule, Rosetta Genomics did note that the Nasdaq provided the company with an extension of a deadline to meet the market value, equity and net income requirement. The company must achieve certain milestones toward regaining compliance by Feb. 28 and April 29.

------------------
Dilution Dilution and more dilution.

Rosetta Genomics Initiates Closing of Private Placement
PR NewswirePress Release: Rosetta Genomics, Ltd. – Wed, Oct 19, 2011 6:09 PM EDT


PHILADELPHIA and REHOVOT, Israel, Oct. 19, 2011 /PRNewswire/ -- Rosetta Genomics, Ltd. ("Rosetta") (NASDAQ:ROSG - News), a leading developer and provider of microRNA-based molecular diagnostics, today announced that it has initiated the closing of its previously announced private placement and expects to receive $1.5 million in gross proceeds. The Company expects to issue an aggregate of 2,025,001 ordinary shares at a price of $0.75 per share. Series A warrants to purchase up to an aggregate of 2,025,001 ordinary shares at an exercise price of $1.00 per share and Series B warrants to purchase up to an aggregate of 1,012,501 ordinary shares at an exercise price equal to the greater of $0.01 or NIS 0.04 per share. Three affiliated investors that had entered into the definitive purchase agreement to purchase an aggregate of 573,000 ordinary shares have notified the Company that they do not intend to deliver payment for the shares. The net proceeds to Rosetta from the private placement, after deducting placement agent fees and other offering expenses payable by Rosetta, are expected to be approximately $1.3 million.


You bought ROSG on Nov 21st when it was clearly breaking down. look at the neg divergence of the accum/dist. The MACD was sick. The price had been at .42 then the day before you bought it dropped to .40. The stock had very little volume. What it did have was sells that took it down everytime. The Oct private placement nice way of saying dilution coming and it did Nov 22, a million shares traded and to the price to .20 on a Monster gap down.

Problem with dilution is you don't know when or how much is coming at any given time. It screws with the best TA. What you do know or should is that about 99% of companies that go down the path ROSG is going down will go sub-penny and eventually r/s and POOF gone or remorph into some other shell.

ROSG looks to be having enough trouble closing the gap. If it can't do that then back to .20 and lower.